anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a holding system for monitoring an automated external defibrillator (AED), comprising: a holding device in which an AED with a state display unit is accommodated and which has a first communication unit; and a server including a second communication unit which is in communication with the first communication unit. According to the present invention, the holding device and the server communicate with each other through the first communication unit and the second communication unit so that the state of the AED accommodated in the holding device can be consistently monitored and necessary actions can be taken immediately according to the monitoring results. A camera unit provided in the holding device consistently monitors the state display unit of the AED. Accordingly, when a battery of the AED is discharged, an operator can check the discharged battery and supply power to the battery by using a wireless charging module. A power state of the AED is visually displayed on the display unit provided in the holding device. Accordingly, users can immediately check the state of the AED regardless of the product type of the AED. In addition, a notification unit provided in the holding device outputs sound or light when an opening/closing unit is opened. Accordingly, an operator can quickly notify people around him or her that an emergency using the AED has occurred.
Patients with Ventricular Tachycardia (VT) who have failed standard therapy (medicines, invasive catheter ablation) have limited options, with one-year survival below 20%. Preclinical data demonstrate that single fraction stereotactic body radiotherapy (SBRT) to discrete portions of the heart is feasible and may result in a reduction or elimination of VT. The efficacy may be further improved when guided by cardiac electrophysiologic (EP) testing. In total, the mapping and ablation proposed for this EP-guided Noninvasive Cardiac Radioablation (ENCORE) is a rapid and totally non-invasive method. Overall safety and early efficacy of ENCORE have not been rigorously studied in a prospective trial to-date. The purpose of this phase I/II study is to demonstrate the short-term safety and preliminary efficacy of ENCORE for patients with life-threatening, treatment-refractory VT.
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors. 

Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets and other agents that affect the RAS.

Do not coadminister aliskiren with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets in patients with diabetes [see Contraindications (4)]. Avoid use of aliskiren with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets in patients with renal impairment (GFR <60 ml/min). 

Use with Colesevelam Hydrochloride: Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. Administration of olmesartan at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose [see Clinical Pharmacology (12.3)].

Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of olmesartan or thiazide diuretics. Monitor lithium levels in patients receiving olmesartan medoxomil, amlodipine, and hydrochlorothiazide and lithium.
This study aimed to establish whether Heart Rate Variance (HRV) biofeedback improved HRV coherence as well as psychological well-being (depression, anxiety, emotion regulation, and mindfulness) over the course of 15 biofeedback sessions in a sample of 14 patients with varying diagnoses; Paranoid Schizophrenia, Schizoaffective Disorder, Personality Disorder or Mixed Diagnosis. All 14 participants (n=10 male, n=4 female) participated in 15 biofeedback sessions. The study was researched and treatment was facilitated by a trainee forensic psychologist working with both male and female offenders residing within a Forensic Psychiatric Hospital, on both low and medium secure wards. An average coherence percentage was captured using the Wild Devine Programme® Relaxing Rhythms software for each session. Quantitative data were collected and analysed before, during and after biofeedback treatment to assess whether there was improvement in psychometric measures of depression, anxiety, emotion regulation and facets of mindfulness. A quasi experimental 'A-B-A design' was employed to assess the research questions.
Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
PURPOSE: A dental composition containing an Euonymus alatus(Thunb.) Sieb. extract for inhibiting the growth of microorganism in the buccal cavity is provided which is effective in the prevention and treatment of dental caries and periodontal disease and can exert an effect sufficiently even in a low concentration. CONSTITUTION: The dental composition contains 0.01 to 5.0% by weight of an Euonymus alatus(Thunb.) Sieb. extract obtained by extraction 2 to 10 times in water, methanol, acetone, 1,3-butylene glycol or a mixture thereof, based on the total weight of the composition. The composition is formulated into a toothpaste, transparent toothpaste, mouth-refreshing agent.
For the first TMS session, participants will receive a single TMS pulse during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 300 pulses. For the second TMS session, participants will receive single pulse TMS during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 200 pulses.
Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
Hepatorenal syndrome (HRS) is a major complication of cirrhosis; it is characterized by functional renal failure and poor prognosis. Arterial dilation is a key pathogenic event of HRS, leading to reduction of the effective blood volume, homeostatic activation of vasoactive systems and renal vasoconstriction with decrease in renal blood flow. The clinical signs of HRS vary depending on the clinical pattern. HRS type 1 is characterized by a rapidly progressive renal failure; HRS type 2 by a moderate and more stable renal failure. HRS type 1 has a very poor short term prognosis, with a median survival of only about 2 weeks; patients with HRS type 2 have a median survival of about 6 months. The management of HRS still constitutes a major challenge. Liver transplantation is the ideal treatment, but it has important inherent drawbacks, such as the organ shortage and the time needed to perform the transplant, that is too long to consent the survival of these patients. The management of HRS has focused on improving renal function, thus extending patients survival and allowing the performance of the liver transplant. In the last years, remarkable results have been obtained using vasoconstrictor drugs. By improving the effective blood volume, vasoconstrictors induce the suppression of homeostatic vasoactive systems and increase renal blood flow and glomerular filtration rate.Among vasoconstrictors, terlipressin, a V1 vasopressin agonist, has currently the best efficacy pedigree. However, it is expensive and is not available in many countries, including North America. More recently, it was suggested that alpha-adrenergic drugs such noradrenalin and midodrine may be also effective in HRS. Noradrenalin would have the potential advantage of wider availability and of lower cost. The current prospective randomized study was undertaken to assess the efficacy and safety of noradrenalin vs terlipressin in patients with HRS.
This randomized, double-blind placebo-controlled parallel group study will be conducted with patients who have experienced a flare of osteoarthritis of the knee. At screening, patients whose pain is currently controlled by an analgesic will agree, after giving Informed Consent, to discontinue that analgesic. Eligible patients will be randomized (1:1 ratio) to receive double-blind treatment with either the ketoprofen topical patch or a matching placebo patch to be applied once daily for 28 days. Patients will return to the clinic on Days 7, 14, 21 and 28. At Day 28, patients may choose to open a 2 month open-label period.

Patients will rate their pain using the Knee Injury and Osteoarthritis Outcome Score (KOOS) which contains the WOMAC pain subscale. Patients will also complete an electronic diary in which pain intensity, pain relief, and quality of sleep ratings will be captured. In addition, rescue medication consumption data will be collected. Ibuprofen will be provided as prn rescue medication.
The licensing of antifibrotic therapy for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF), has created an urgent need for reliable biomarkers to predict disease progression and treatment response. Some patients experience stable disease trajectories, while others deteriorate rapidly, making treatment decisions challenging. High-resolution chest CT has become crucial for diagnosis, but visual assessments by radiologists suffer from low reproducibility and high interobserver variability. To address these issues, computer-based image analysis, called quantitative CT, has emerged. However, many quantitative CT methods rely on human input for training, therefore potentially incorporating human error into computer training. Rapid advances in artificial intelligence, specifically deep learning, aim to overcome this limitation by enabling autonomous quantitative analysis. While promising, deep learning also presents challenges including the need to minimize algorithm biases, ensuring explainability, and addressing accessibility and ethical concerns. This review explores the development and application of deep learning in improving the imaging process for fibrotic lung disease.
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are frequently used for preclinical cardiotoxicity testing and remain an important tool for confirming model-based predictions of drug effects in accordance with the comprehensive in vitro proarrhythmia assay (CiPA). Despite the considerable benefits hiPSC-CMs provide, concerns surrounding experimental reproducibility have emerged. We investigated the effects of temporal changes and experimental parameters on hiPSC-CM electrophysiology. iCell cardiomyocytes2 were cultured and biosignals were acquired using a microelectrode array (MEA) system (2-14 days). Continuous recordings revealed a 22.6% increase in the beating rate and 7.7% decrease in the field potential duration (FPD) during a 20-min equilibration period. Location-specific differences across a multiwell plate were also observed, with iCell cardiomyocytes2 in the outer rows beating 8.8 beats/min faster than the inner rows. Cardiac endpoints were also impacted by cell culture duration; from 2 to 14 days, the beating rate decreased (-12.7 beats/min), FPD lengthened (+257 ms), and spike amplitude increased (+3.3 mV). Cell culture duration (4-10 days) also impacted cardiomyocyte drug responsiveness (E-4031, nifedipine, isoproterenol). qRT-PCR results suggest that daily variations in cardiac metrics may be linked to the continued maturation of hiPSC-CMs in culture (2-30 days). Daily experiments were also repeated using a second cell line (Cor.4U). Collectively, our study highlights multiple sources of variability to consider and address when performing hiPSC-CM MEA studies. To improve reproducibility and data interpretation, MEA-based studies should establish a standardized protocol and report key experimental conditions (e.g., cell line, culture time, equilibration time, electrical stimulation settings, and raw data values).NEW & NOTEWORTHY We demonstrate that iCell cardiomyocytes2 electrophysiology measurements are impacted by deviations in experimental techniques including electrical stimulation protocols, equilibration time, well-to-well variability, and length of hiPSC-CM culture. Furthermore, our results indicate that hiPSC-CM drug responsiveness changes within the first 2 wk following defrost.
PURPOSE:To obtain a new compound useful for preventing and treating hypoxemia due to diseases in respiratory organs. CONSTITUTION:This compound is expressed by formula I [R<1> is H, alkyl, alkenyl, etc.; R<2> is an alkyl, alkenyl or aralkyl; R<2> is H or a 1-3C alkyl; Z is 4-to 7-membered heteroalicyclic group), e.g. 2-al lylamino-4-(4- tetrahydropyranyl)-amino-7-methyl-7H--pyrrolo[2,3-d]pyrimidine. The compound expressed by formula I is obtained by reacting a compound expressed by formula II (X is halogen) with an amine expressed by formula III under alkaline conditions. The compound expressed by formula I is capable of enhancing the respiratory function in the lungs. Some thereof are capable of raising only the partial pressure of oxygen mainly in arterial blood and some have action on reduction in the partial pressure of gaseous carbon dioxide in the arterial blood together with a rise in the partial pressure of oxygen in the arterial blood.
Patients undergo an optional saliva/buccal swab in part 1 and clinical assessment in part 2 of the study. Patients may then undergo blood sample collection in part 3 of the study.
Techniques for providing acoustic feedback are disclosed. Several audio segments (21-23) have synchronized beats. The sensor signal (16) received from the sensor has a sensor signal range which is divided by a first threshold value and a second threshold value (11, 12) into at least three sensor signal sub-ranges (13-15). An audio signal is output in response to the received sensor signal (16), the output audio signal comprising one or more audio segments. If the received sensor signal (16) exceeds a first threshold value (11), at least one of the one or more audio segments (21) is stopped and/or at least one additional one of the audio segments (22) is started in synchronization with the one or more audio segments (21). If the received sensor signal (16) is below the second threshold value (12), at least one of the one or more audio segments (21) is stopped and/or at least one additional one of the audio segments (23) is started in synchronization with the one or more audio segments (21).
Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting ciprofloxican. Patients of any age or without pre-existing risk factors have experienced these adverse reactions [see Warnings and Precautions (5.2, 5.3, 5.4)].

Discontinue ciprofloxican immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including ciprofloxican, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.
Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
Chronic hepatitis B virus (HBV) infection is a significant global public health concern, and the clearance of HBV is closely linked to the activity of HBV-specific T cells, which is regulated by various co-suppressor molecules. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is among these co-suppressor molecules which induces T cell exhaustion by competitively inhibiting CD28 and dampening the function of HBV-specific T cells. CTLA-4 also plays a role in the regulation of T helper (Th) cell differentiation and influences cytokine release. In addition, CTLA-4 can impact glucose metabolism in hepatocellular carcinoma through its interaction with T regulatory (Treg) cells. This review aims to provide a comprehensive overview of the existing literature related to the role of CTLA-4 in HBV patients across different subsets of T cells. Additionally, we propose a discussion on the possible mechanisms through which CTLA-4 may contribute to HBV infection, as well as the development of HBV-induced cirrhosis and hepatocellular carcinoma.
The present invention relates to a method for structuring balanced and varied meals, and this method is characterized in that a database is constituted comprising all the varieties of dishes available during a given period, and the features of their constituents, which are selected from this database, for each meal, from the available dishes, those complying with the food restrictions relative to this user and constituting a balanced meal, and that the user chooses from these dishes those that he prefers. The database consists of preestablished lists of ingredients, recipes, dishes and meals. These lists are characterized in that each of the constituents of this database is coded according to its nutritional, therapeutic, budgetary, target consumer, etc. properties. The filter of the database is generated dynamically on the basis of the prior information and with the aid of the codes of the dishes (or of the meals). In other words, the entry of the prior information serves to define requests.
Propriospinal myoclonus at sleep onset (PSM-S) is a sudden myoclonic jerk that occurs during the transition from wakefulness to sleep. It is a sleep-related movement disorder that causes difficulty falling asleep due to involuntary movements that spread caudally and rostrally through the propriospinal tract. Diagnosis requires observation of movements and polysomnography (PSG), and there are few reports. An 80-year-old man was referred to our center for insomnia due to abdominal movements at sleep onset. During the EEG test, we observed the caudal and rostral propagation of movements emanating from the abdomen. Attended video-PSG with additional surface electromyography revealed that myoclonic jerks occurred during the transition from wake to stage N1 and disappeared during sleep stage N2. EMG activity originated from the rectus abdominis muscle, followed by rostral and caudal propagation. Here, we report a case demonstrating that PSG with additional surface electromyography is important and useful for the diagnosis of PMS at sleep onset.
Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
<P>PROBLEM TO BE SOLVED: To obtain a new Maillard reaction inhibitor having high safety and a skin care preparation and a food and beverage.  <P>SOLUTION: The Maillard reaction inhibitor has high safety and a Maillard reaction inhibiting effect and comprises a plant extract selected from putamen of Ziziphus zizyphus (Rhamnaceae), Malva nut of MACJONG (Sterculia lychnophera), seed of Cucurbita moschata(Cucurbitaceae), leaf of Eucommia ulmoildes (Eucommiaceae), root of Salacia oblonga (Celastraceae) and leaf of Chimaphila umbellata. (L.) W. Barton (Pyrolaceae). The antiaging skin care preparation comprises the Maillard reaction inhibitor. The food and beverage each comprise the Maillard reaction inhibitor.  <P>COPYRIGHT: (C)2008,JPO&INPIT
ABSTRACT OF THE DISCLOSURE         A controlled-release composition for a biologically active material, wherein said active material has been dissolved or dispersed in an L2-phase comprising (a) at least one monoglyceride of an unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such a monoglyceride, (b) at least one triglyceride of at least one unsaturated fatty acid having 16 22 carbon atoms or a vegetable or animal oil containing such triglycerides, and (c) at least one polar liquid selected from the group consisting of water, glycerol, ethylene glycol and propylene glycol  Such L2-phases are known per se but are novel in this context.  The composition is prepared by forming the L2-phase and adding the biologically active material before, during or after the formation of the L2-phase.  For sensitive substances such as proteins a mixture of the mono- and triglycerides is added dropwisely to a solution of  said substance in the polar liquid.  The composition is thermodynamically stable and has no tendency to separate with time.  It has distinct hydrophilic and hydrophobic domains, which enables it to solubilize both water-soluble and water-insoluble compounds.  The composition is useful for encapsulating a biologically active material, such as pharmaceutical compounds, pesticides, fertilizers and feromones, to obtain a preparation giving a controlled release of the encapsulated material.
A kidney and spleen traditional Chinese medicinal injection without relieving exterior syndrome and a production method. The formula of the injection contains the following components of: 1g of anemarrhena, 1g of Dictamnus dasycarpus Turcz, 1g of pseudobulubs cremastrae seu pleiones, 0.5g of Betula platyphylla, 1g of radix scrophulariae, 1g of buck grass, 1g of Geranium strictipes R.Knuth, 1g of Villous Amomum Fruit, 1g of Poria cocos, 1g of Abrus cantoniensis, 1g of Chinese prickly ash, 1g of combined spicebush, 1g of myrrh, 1g of rhizoma drynariae, 1g of Diverse Wormwood Herb, 1g of Chinese yam, 1g of Psoralea corylifolia, 1g of sharpleaf galangal fruit, 1g of cowpea and 1g of lotus seed. Production links comprise: batching, cleaning, drying, sterilization, crushing into powders, cell rupture, multiple filtration, filling, filling rubber plug, capping, lamp inspection, specification pasting, packaging, storing and examination. The kidney and spleen traditional Chinese medicinal injection needs no decoction, doesn't pass through pores and sweat pores, and is suitable for treating patients with kidney and spleen tissue diseases such as hyperhidrosis, polyuria and multi-delays. By the adoption of the production method, the medicinal components in all the traditional Chinese medicines can be retained. The production method relates to the production of the kidney and spleen traditional Chinese medicinal injection.